Effects of Fenofibrate on the Safety, Toleration and Efficacy Biomarkers of CP-742,033
This study has been withdrawn prior to enrollment.
Information provided by:
First received: September 13, 2006
Last updated: December 11, 2006
Last verified: December 2006
The purpose of this study is to determine whether fenofibrate effects the toleration, safety, or efficacy biomarkers of CP-742,033, a drug being developed for the treatment of obesity.
|Study Design:||Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Single Blind
Primary Purpose: Treatment
|Official Title:||A Phase 1, Randomized, Investigator and Subject Blind, Sponsor Open Study to Determine the Effects of Fenofibrate on the Safety, Toleration and Efficacy Biomarkers of CP-742,033 When Co-Administered in Otherwise Healthy Obese Adult Subjects|
Resource links provided by NLM:
Further study details as provided by Pfizer:
Contacts and Locations